Trial Profile
Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Biogen
- 26 Oct 2006 Status change
- 25 Oct 2005 New trial record.